Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) EPS (Weighted Average and Diluted) (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.14 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 17.65% year-over-year to -$0.14, compared with a TTM value of -$0.8 through Dec 2025, up 6.98%, and an annual FY2025 reading of -$0.8, up 6.98% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.14 for Q4 2025 at aTYR PHARMA, up from -$0.27 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.14 in Q4 2025 and bottomed at -$0.65 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.3, with a median of -$0.24 recorded in 2024.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 61.06% in 2021, while the deepest fall reached 304.0% in 2021.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.21 in 2021, then decreased by 23.81% to -$0.26 in 2022, then increased by 3.85% to -$0.25 in 2023, then soared by 32.0% to -$0.17 in 2024, then increased by 17.65% to -$0.14 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ATYR at -$0.14 in Q4 2025, -$0.27 in Q3 2025, and -$0.22 in Q2 2025.